269 related articles for article (PubMed ID: 24809953)
1. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
[TBL] [Abstract][Full Text] [Related]
2. Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
Medapi B; Meda N; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2016 Feb; 24(4):877-85. PubMed ID: 26787274
[TBL] [Abstract][Full Text] [Related]
3. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.
Reck F; Alm RA; Brassil P; Newman JV; Ciaccio P; McNulty J; Barthlow H; Goteti K; Breen J; Comita-Prevoir J; Cronin M; Ehmann DE; Geng B; Godfrey AA; Fisher SL
J Med Chem; 2012 Aug; 55(15):6916-33. PubMed ID: 22779424
[TBL] [Abstract][Full Text] [Related]
4. Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Bobesh KA; Renuka J; Srilakshmi RR; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2016 Jan; 24(1):42-52. PubMed ID: 26678175
[TBL] [Abstract][Full Text] [Related]
5. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
[TBL] [Abstract][Full Text] [Related]
6. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.
Ouchi Y; Mukai T; Koide K; Yamaguchi T; Park JH; Kim H; Yokoyama K; Tamaru A; Gordon SV; Nakajima C; Suzuki Y
Tuberculosis (Edinb); 2020 Jan; 120():101891. PubMed ID: 31778929
[TBL] [Abstract][Full Text] [Related]
7. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
[TBL] [Abstract][Full Text] [Related]
8. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.
Jeankumar VU; Renuka J; Pulla VK; Soni V; Sridevi JP; Suryadevara P; Shravan M; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Int J Antimicrob Agents; 2014 Mar; 43(3):269-78. PubMed ID: 24434114
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
[TBL] [Abstract][Full Text] [Related]
11. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.
Reck F; Alm R; Brassil P; Newman J; Dejonge B; Eyermann CJ; Breault G; Breen J; Comita-Prevoir J; Cronin M; Davis H; Ehmann D; Galullo V; Geng B; Grebe T; Morningstar M; Walker P; Hayter B; Fisher S
J Med Chem; 2011 Nov; 54(22):7834-47. PubMed ID: 21999508
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.
Gibson EG; Blower TR; Cacho M; Bax B; Berger JM; Osheroff N
ACS Infect Dis; 2018 Aug; 4(8):1211-1222. PubMed ID: 29746087
[TBL] [Abstract][Full Text] [Related]
14. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
Chopra S; Matsuyama K; Tran T; Malerich JP; Wan B; Franzblau SG; Lun S; Guo H; Maiga MC; Bishai WR; Madrid PB
J Antimicrob Chemother; 2012 Feb; 67(2):415-21. PubMed ID: 22052686
[TBL] [Abstract][Full Text] [Related]
16. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
Matrat S; Veziris N; Mayer C; Jarlier V; Truffot-Pernot C; Camuset J; Bouvet E; Cambau E; Aubry A
Antimicrob Agents Chemother; 2006 Dec; 50(12):4170-3. PubMed ID: 17015625
[TBL] [Abstract][Full Text] [Related]
18. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
[TBL] [Abstract][Full Text] [Related]
19. Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).
Singh SB; Kaelin DE; Meinke PT; Wu J; Miesel L; Tan CM; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Takeuchi T; Takano H; Ohata K; Kurasaki H; Nishimura A; Shibata T; Fukuda Y
Bioorg Med Chem Lett; 2015 Sep; 25(17):3630-5. PubMed ID: 26152426
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
